Medscape Pharmacists Podcast

Dr Kuchay discusses his findings from the E-LIFT study.

Cutting the risk for natalizumab-related PML, update on disability outcomes with ibudilast, and daclizumab pulled from the global market.

Dr Paul Sax reports on an intriguing two-drug regimen that could become the standard of care in preventing TB.

Dr Peter Yellowlees talks about the association between hormonal contraception and suicide.

Drs Budoff and Baum discuss the topline results of the ODYSSEY trial presented at the 2018 ACC meeting and hope for easier access to PCSK9 inhibitors for their high-risk patients.

Dr Richard Isaacson on why this new formulation of an ingredient available in most spice racks may be proving effective.

Dr David Kerr on how this time-tested drug enhances more complex and expensive immunotherapies.

Despite the abandonment of research by some pharmaceutical companies, Dr Isaacson is very hopeful about the future of Alzheimer disease treatment and prevention.

Dr Szczech discusses the emotional challenges that patients with CKD face in their transition to dialysis, and offers suggestions to PCPs and pharmacists who see these patients.

Dr Peters clarifies the pros and cons of the Dexcom and FreeStyle Libre continuous glucose monitors for patients with diabetes.